Lung Adenocarcinoma: Correlation between mRNA expression and clinical features
Maintained by TCGA GDAC Team (Broad Institute/Dana-Farber Cancer Institute/Harvard Medical School)
Overview
Introduction

This pipeline uses various statistical tests to identify mRNAs whose expression levels correlated to selected clinical features.

Summary

Testing the association between 17814 genes and 7 clinical features across 32 samples, statistically thresholded by Q value < 0.05, 2 clinical features related to at least one genes.

- 1 gene correlated to 'GENDER'.

- MRPL3

- 1 gene correlated to 'PATHOLOGY.T'.

- PAPPA2

- No genes correlated to 'Time to Death', 'AGE', 'KARNOFSKY.PERFORMANCE.SCORE', 'PATHOLOGY.N', and 'NEOADJUVANT.THERAPY'.

Results
Overview of the results

Complete statistical result table is provided in Supplement Table 1

Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of genes that are significantly associated with each clinical feature at Q value < 0.05.

Clinical feature | Statistical test | Significant genes | Associated with |  | Associated with |
--- | --- | --- | --- | --- | --- | ---
Time to Death | Cox regression test | N=0 |  |  |  |
AGE | Spearman correlation test | N=0 |  |  |  |
GENDER | t test | N=1 | male | N=1 | female | N=0
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=0 |  |  |  |
PATHOLOGY T | Spearman correlation test | N=1 | higher pT | N=0 | lower pT | N=1
PATHOLOGY N | Spearman correlation test | N=0 |  |  |  |
NEOADJUVANT THERAPY | t test | N=0 |  |  |  |

Clinical variable #1: 'Time to Death'

No gene related to 'Time to Death'.

Table S1. Basic characteristics of clinical feature: 'Time to Death'

Time to Death | Duration (Months) | 0.5-56.8 (median=8.3)
| censored | N = 27
| death | N = 4
| Significant markers | N = 0

Clinical variable #2: 'AGE'

No gene related to 'AGE'.

Table S2. Basic characteristics of clinical feature: 'AGE'

AGE | Mean (SD) | 65.7 (11)
| Significant markers | N = 0

Clinical variable #3: 'GENDER'

One gene related to 'GENDER'.

Table S3. Basic characteristics of clinical feature: 'GENDER'

GENDER | Labels | N
| FEMALE | 18
| MALE | 14
| Significant markers | N = 1
| Higher in MALE | 1
| Higher in FEMALE | 0

List of one gene differentially expressed by 'GENDER'

Table S4. Get Full Table List of one gene differentially expressed by 'GENDER'

| T(pos if higher in 'MALE') | ttestP | Q | AUC
--- | --- | --- | --- | ---
MRPL3 | 5.98 | 2.266e-06 | 0.0404 | 0.9405

Figure S1. Get High-res Image As an example, this figure shows the association of MRPL3 to 'GENDER'. P value = 2.27e-06 with T-test analysis.

Clinical variable #4: 'KARNOFSKY.PERFORMANCE.SCORE'

No gene related to 'KARNOFSKY.PERFORMANCE.SCORE'.

Table S5. Basic characteristics of clinical feature: 'KARNOFSKY.PERFORMANCE.SCORE'

KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 56.67 (49)
| Score | N
| 0 | 1
| 80 | 1
| 90 | 1
| Significant markers | N = 0

Clinical variable #5: 'PATHOLOGY.T'

One gene related to 'PATHOLOGY.T'.

Table S6. Basic characteristics of clinical feature: 'PATHOLOGY.T'

PATHOLOGY.T | Mean (SD) | 1.66 (0.55)
|  | N
| T1 | 12
| T2 | 19
| T3 | 1
| Significant markers | N = 1
| pos. correlated | 0
| neg. correlated | 1

List of one gene significantly correlated to 'PATHOLOGY.T' by Spearman correlation test

Table S7. Get Full Table List of one gene significantly correlated to 'PATHOLOGY.T' by Spearman correlation test

| SpearmanCorr | corrP | Q
--- | --- | --- | ---
PAPPA2 | -0.7603 | 4.455e-07 | 0.00794

Figure S2. Get High-res Image As an example, this figure shows the association of PAPPA2 to 'PATHOLOGY.T'. P value = 4.45e-07 with Spearman correlation analysis.

Clinical variable #6: 'PATHOLOGY.N'

No gene related to 'PATHOLOGY.N'.

Table S8. Basic characteristics of clinical feature: 'PATHOLOGY.N'

PATHOLOGY.N | Mean (SD) | 0.39 (0.72)
|  | N
| N0 | 23
| N1 | 4
| N2 | 4
| Significant markers | N = 0

Clinical variable #7: 'NEOADJUVANT.THERAPY'

No gene related to 'NEOADJUVANT.THERAPY'.

Table S9. Basic characteristics of clinical feature: 'NEOADJUVANT.THERAPY'

NEOADJUVANT.THERAPY | Labels | N
| NO | 6
| YES | 26
| Significant markers | N = 0

Methods & Data
Input

- Expresson data file = LUAD.medianexp.txt

- Clinical data file = LUAD.clin.merged.picked.txt

- Number of patients = 32

- Number of genes = 17814

- Number of clinical features = 7

Survival analysis

For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels

Correlation analysis

For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R

Student's t-test analysis

For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] Andersen and Gill, Cox's regression model for counting processes, a large sample study, Annals of Statistics 10(4):1100-1120 (1982)
[2] Spearman, C, The proof and measurement of association between two things, Amer. J. Psychol 15:72-101 (1904)
[3] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)
Copyright © 2011 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle